Jan P van Meerbeeck
Overview
Explore the profile of Jan P van Meerbeeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
4371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Racovita M, Wheeler E, Wait S, Albreht T, Baird A, Jassem J, et al.
Eur J Cancer
. 2022 Sep;
175:54-59.
PMID: 36088672
Lung cancer is the leading cause of cancer-related deaths in Europe. Europe's Beating Cancer Plan calls for a comprehensive approach to the disease in general but not specifically to lung...
12.
Raskin J, Snoeckx A, Janssens A, De Bondt C, Wener R, van de Wiel M, et al.
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884463
This paper describes where and how sex matters in today's management of lung cancer. We consecutively describe the differences between males and females in lung cancer demographics; sex-based differences in...
13.
Janssens E, Schillebeeckx E, Zwijsen K, Raskin J, Cleemput J, Surmont V, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804954
During the past decade, volatile organic compounds (VOCs) in exhaled breath have emerged as promising biomarkers for malignant pleural mesothelioma (MPM). However, as these biomarkers lack external validation, no breath...
14.
Janssens E, Mol Z, Vandermeersch L, Lagniau S, Vermaelen K, van Meerbeeck J, et al.
Front Oncol
. 2022 May;
12:851785.
PMID: 35600344
Introduction: Malignant pleural mesothelioma (MPM) is a lethal cancer for which early-stage diagnosis remains a major challenge. Volatile organic compounds (VOCs) in breath proved to be potential biomarkers for MPM...
15.
van Meerbeeck J, ODowd E, Ward B, Van Schil P, Snoeckx A
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565472
Randomized-controlled trials have shown clear evidence that lung cancer screening with low-dose CT in a high-risk population of current or former smokers can significantly reduce lung-cancer-specific mortality by an inversion...
16.
Kindler H, Novello S, Bearz A, Ceresoli G, Aerts J, Spicer J, et al.
Lancet Oncol
. 2022 Mar;
23(4):540-552.
PMID: 35358455
Background: Few treatment options exist for second-line treatment of malignant pleural mesothelioma. We aimed to assess the antibody-drug conjugate anetumab ravtansine versus vinorelbine in patients with unresectable locally advanced or...
17.
Rovers S, Janssens A, Raskin J, Pauwels P, van Meerbeeck J, Smits E, et al.
Biomedicines
. 2022 Mar;
10(3).
PMID: 35327475
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of...
18.
Racovita M, Wheeler E, Wait S, Bancroft D, Eastabrook R, Albreht T, et al.
Tob Prev Cessat
. 2022 Mar;
8:06.
PMID: 35233474
No abstract available.
19.
Schillebeeckx E, van Meerbeeck J, Lamote K
Eur Respir Rev
. 2021 Nov;
30(162).
PMID: 34789461
Malignant pleural mesothelioma (MPM) is characterised by late-stage diagnosis and poor prognosis. Currently, no screening tool is advocated and diagnosis is based on invasive techniques, which are not well tolerated....
20.
Ocak S, Tournoy K, Berghmans T, Demedts I, Durieux R, Janssens A, et al.
J Thorac Oncol
. 2021 Sep;
16(10):1610-1621.
PMID: 34561034
No abstract available.